Effect of Fenugreek Extract on Testosterone Propionate-Induced Benign Prostatic Hyperplasia

被引：0

作者：

Lee, Jeong Yoon ^{[1
]}

Bang, Jiyoung ^{[1
]}

Kim, Jinhak ^{[2
]}

Baek, Kwang-Soo ^{[2
]}

Oh, Dongchan ^{[2
]}

Lee, Yoo-Hyun ^{[1
]}

机构：

[1] Univ Suwon, Dept Food & Nutr, Hwaseong 445743, South Korea

[2] Daehan Chemtech Co Ltd, R&D Div, Gwacheon Si 13840, South Korea

来源：

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES | 2025年 / 26卷 / 03期

关键词：

fenugreek seed extract; benign prostatic hyperplasia; androgen receptor; dihydrotestosterone; NF-KAPPA-B; INFLAMMATION; VITEXIN; ALPHA;

D O I：

10.3390/ijms26031261

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Benign prostatic hyperplasia (BPH) is a noncancerous urinary disorder that is common in older adult men; however, its underlying mechanisms remain unclear. Fenugreek has some biological effects, including hyperglycemia regulation, immune response modulation, and anti-cancer properties; In this study, we investigated the ameliorative effects of fenugreek seed extract (Forceterone (R) [FCT]) in a testosterone propionate (TP)-induced BPH animal model and its mechanisms in BPH-1 human prostate epithelial cells. Sprague Dawley (SD) rats were injected subcutaneously with TP (3 mg/kg) for 8 weeks to induce BPH while FCT was administered orally at 25, 50, and 100 mg/kg. In addition, BPH-1 cells were used to evaluate the inhibitory effects on cell proliferation and examine inflammatory cytokine expression. Treating rats with FCT decreased prostate weight, dihydrotestosterone (DHT) level, and proliferating cell nuclear antigen (PCNA) expression in the prostate. Furthermore, it decreased androgen receptor (AR), 5 alpha-reductase 2, B-cell lymphoma 2 (Bcl-2), interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-alpha), and NF-kappa B expression in vitro and in vivo and increased Bcl-2-associated X protein (Bax) expression. FCT also inhibited cell proliferation dose dependently in BPH-1 cells. These findings showed the potential use of FCT as an alternative treatment for BPH.

引用

页数：16

共 44 条

[1] Passos G.R., Ghezzi A.C., Antunes E., de Oliveira M.G., Monica F.Z., The Role of Periprostatic Adipose Tissue on Prostate Function in Vascular-Related Disorders, Front. Pharmacol, 12, (2021)
[2] Xie Z., Liu X., Hu Z., Dong C., Longitudinal Association between the Dynamic Nature of Depression with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH), BMC Public Health, 24, (2024)
[3] Chess-Williams R., McDermott C., Sellers D.J., West E.G., Mills K.A., Chronic Psychological Stress and Lower Urinary Tract Symptoms, Low. Urin. Tract Symptoms, 13, pp. 414-424, (2021)
[4] Csikos E., Horvath A., Acs K., Papp N., Balazs V.L., Dolenc M.S., Kenda M., Glavac N.K., Nagy M., Protti M., Et al., Treatment of Benign Prostatic Hyperplasia by Natural Drugs, Molecules, 26, (2021)
[5] Miernik A., Gratzke C., Current Treatment for Benign Prostatic Hyperplasia, Dtsch. Arztebl. Int, 117, pp. 843-854, (2020)
[6] Shin Y.S., Karna K.K., Choi B.R., Park J.K., Finasteride and Erectile Dysfunction in Patients with Benign Prostatic Hyperplasia or Male Androgenetic Alopecia, World J. Men’s Health, 37, pp. 157-165, (2019)
[7] Li Y., Ma J., Qin X.H., Hu C.Y., The Efficacy and Safety of Dutasteride and Finasteride in Patients with Benign Prostatic Hyperplasia: A Systematic Review and Meta-Analysis, Transl. Androl. Urol, 11, pp. 313-324, (2022)
[8] Cannarella R., Condorelli R.A., Barbagallo F., La Vignera S., Calogero A.E., Endocrinology of the Aging Prostate: Current Concepts, Front. Endocrinol, 12, (2021)
[9] Deslypere J.P., Young M., Wilson J.D., McPhaul M.J., Testosterone and 5 Alpha-Dihydrotestosterone Interact Differently with the Androgen Receptor to Enhance Transcription of the MMTV-CAT Reporter Gene, Mol. Cell. Endocrinol, 88, pp. 15-22, (1992)
[10] Tong Y., Zhou R.Y., Review of the Roles and Interaction of Androgen and Inflammation in Benign Prostatic Hyperplasia, Mediat. Inflamm, 2020, (2020)

← 1 2 3 4 5 →